ADMA Biologics Inc vs Moody's Corporation — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Moody's Corporation trades at $475 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 37.2× ADMA Biologics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MCO | |
|---|---|---|
Market Cap | $2.22B | $82.52B |
Sector | Health | Financials |
52-Week High | $20.38 | $539.61 |
52-Week Low | $7.60 | $412.23 |
Enterprise Value | $2.29B | $88.54B |
Dividend Yield | — | 0.86% |
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →